In early clinical trials, promising results were reported in patients who show FGFR2 amplification in gastric cancer and in patients with FGFR2 and FGFR3 translocations in cholangiocarcinoma and urothelial cancers, respectively. The gene discussed is FGFR2; the disease is cholangiocarcinoma.